Outlook for a dengue vaccine.

Area of Science:

• Tropical medicine
• Vaccinology
• Virology

Background:

• Dengue presents a growing global health challenge, particularly in tropical and subtropical regions.
• The existence of four distinct dengue virus serotypes complicates vaccine development.
• Live-attenuated vaccine candidates must demonstrate safety, specifically avoiding the induction of severe dengue hemorrhagic fever.

Purpose of the Study:

• To review the progress and challenges in developing a dengue vaccine.
• To assess the efficacy and safety of current leading vaccine candidates.

Main Methods:

• Review of clinical trial data for dengue vaccine candidates.
• Analysis of vaccine performance against different dengue virus serotypes.
• Evaluation of safety profiles, focusing on severe dengue complications.

Main Results:

• One tetravalent chimeric vaccine candidate, derived from a yellow fever virus strain, has advanced to large-scale clinical trials.
• This vaccine demonstrated efficacy against dengue virus types 1 and 3, but not type 2.
• No vaccine-induced dengue hemorrhagic fever was reported for this candidate.

Conclusions:

• A tetravalent dengue vaccine candidate has shown partial success in clinical trials.
• Further development is needed to achieve complete protection against all four dengue serotypes.
• An effective dengue vaccine is anticipated within the next decade, addressing a significant public health need.